These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

613 related items for PubMed ID: 29334901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM, Cornall AM, Brotherton JML, Wark JD, Malloy MJ, Tabrizi SN, VACCINE study group.
    Vaccine; 2018 May 31; 36(23):3221-3230. PubMed ID: 29724506
    [Abstract] [Full Text] [Related]

  • 3. Low prevalence of vaccine-type HPV infections in young women following the implementation of a school-based and catch-up vaccination in Quebec, Canada.
    Goggin P, Sauvageau C, Gilca V, Defay F, Lambert G, Mathieu-C S, Guenoun J, Comète E, Coutlée F.
    Hum Vaccin Immunother; 2018 Jan 02; 14(1):118-123. PubMed ID: 29049007
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
    Dominiak-Felden G, Gobbo C, Simondon F.
    PLoS One; 2015 Jan 02; 10(7):e0132404. PubMed ID: 26147096
    [Abstract] [Full Text] [Related]

  • 6. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection.
    Saccucci M, Franco EL, Ding L, Bernstein DI, Brown D, Kahn JA.
    Sex Transm Dis; 2018 Apr 02; 45(4):260-265. PubMed ID: 29465705
    [Abstract] [Full Text] [Related]

  • 7. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, Malloy M, Garland SM.
    Lancet Infect Dis; 2014 Oct 02; 14(10):958-66. PubMed ID: 25107680
    [Abstract] [Full Text] [Related]

  • 8. Age and geographic variability of human papillomavirus high-risk genotype distribution in a large unvaccinated population and of vaccination impact on HPV prevalence.
    Carozzi F, De Marco L, Gillio-Tos A, Del Mistro A, Girlando S, Baboci L, Trevisan M, Burroni E, Grasso S, Giorgi Rossi P, Ronco G, NTCC Working Group.
    J Clin Virol; 2014 Jul 02; 60(3):257-63. PubMed ID: 24815381
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
    Heard I, Tondeur L, Arowas L, Demazoin M, Falguières M, Parent Du Chatelet I, pour le groupe CHlaHPV.
    J Infect Dis; 2017 Mar 01; 215(5):757-763. PubMed ID: 28011911
    [Abstract] [Full Text] [Related]

  • 10. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women.
    Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de Melker HE.
    J Infect Dis; 2018 Apr 23; 217(10):1579-1589. PubMed ID: 29409034
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
    Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T.
    J Infect Dis; 2019 Jan 09; 219(3):382-390. PubMed ID: 30299519
    [Abstract] [Full Text] [Related]

  • 17. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Shilling H, Garland SM, Atchison S, Cornall AM, Brotherton JML, Bateson D, McNamee K, Kaldor JM, Hocking JS, Chen MY, Fairley CK, McNulty A, Bell C, Marshall L, Ooi C, Skinner SR, Murray G, Molano M, Tabrizi S, Machalek DA.
    Vaccine; 2021 Aug 09; 39(34):4856-4863. PubMed ID: 34281743
    [Abstract] [Full Text] [Related]

  • 18. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis.
    Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG.
    Br J Cancer; 2016 May 24; 114(11):1261-4. PubMed ID: 27115467
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.